Isoferulic acid action against glycation-induced changes in structural and functional attributes of human high-density lipoprotein
- 68 Downloads
Glycation-induced high-density lipoprotein (HDL) modification by aldehydes can result in loss of its antiinflammatory/antioxidative properties, contributing to diabetes-associated cardiovascular diseases. Isoferulic acid, a major active ingredient of Cimicifuga heracleifolia, shows antiinflammatory, antiviral, antioxidant, and antidiabetic properties. Thus, this study investigated the antiglycation effect of isoferulic acid against compositional modifications of HDL and loss of biological activity of HDL-paraoxonase induced on incubation with different aldehydes. Protective effect of isoferulic acid was assessed by subjecting purified HDL from human plasma to glycation with methylglyoxal, glyoxal, or glycolaldehyde and varying concentrations of isoferulic acid. The effect of isoferulic acid was analyzed by determining amino group number, tryptophan and advanced glycation end-product fluorescence, thermal denaturation studies, carboxymethyl lysine content, and activity of HDL-paraoxonase. Concentration-dependent inhibitory action of isoferulic acid was observed against extensive structural perturbations, decrease in amino group number, increase in carboxymethyl lysine content, and decrease in the activity of HDL-paraoxonase caused by aldehyde-associated glycation in the HDL molecule. Isoferulic acid, when taken in concentration equal to that of aldehydes, was most protective, as 82-88% of paraoxonase activity was retained for all studied aldehydes. Isoferulic acid shows antiglycation action against aldehyde-associated glycation in HDL, which indicates its therapeutic potential for diabetic patients, especially those with micro-/macrovascular complications.
Key wordsaldehydes glycation high-density lipoprotein-AGEs isoferulic acid paraoxonase
advanced glycation end products
enzyme linked immunosorbent assay
Unable to display preview. Download preview PDF.
- 4.Karathanasis, S. K. (1992) Lipoprotein metabolism: high-density lipoprotein, in Molecular Genetics of Coronary Artery Disease (Lusis, A. J., Rotter, J. I., and Sparkes, R. S., eds.) Karger, Basel, pp. 140–171.Google Scholar
- 5.Ferretti, G., Bacchetti, T., Busni, D., Rabini, R. A., and Curatola, G. (2004) Protective effect of paraoxonase activity in high-density lipoproteins against erythrocyte membranes peroxidation: a comparison between healthy subjects and type 1 diabetic patients, J. Clin. Endocrinol. Metab., 89, 2957–2962.CrossRefPubMedGoogle Scholar
- 12.Brown, B. E., Mahroof, F. M., Cook, N. L., Van Reyk, D. M., and Davies, M. J. (2006) Hydrazine compounds inhibit glycation of low-density lipoproteins and prevent the in vitro formation of model foam cells from glycolaldehyde-modified low-density lipoproteins, Diabetologia, 49, 775–783.CrossRefPubMedGoogle Scholar
- 16.Bolton, W. K., Cattran, D. C., Williams, M. E., Adler, S. G., Appel, G. B., Cartwright, K., Foiles, P. G., Freedom, B. I., Raskin, P., Ratner, R. E., Spinowitz, B. S., Whittier, F. C., and Wuerth, J. P. (2004) Randomized trial of an inhibitor of formation of advanced glycation end products in diabetic nephropathy, Am. J. Nephrol., 24, 32–40.CrossRefPubMedGoogle Scholar
- 18.Ishibashi, Y., Matsui, T., Takeuchi, M., and Yamagishi, S. (2012) Metformin inhibits advanced glycation end products (AGEs)-induced renal tubular cell injury by suppressing reactive oxygen species generation via reducing receptor for AGEs (RAGE) expression, Horm. Metab. Res., 44, 891–895.CrossRefPubMedGoogle Scholar
- 21.Schmid, D., Woehs, F., Svoboda, M., Thalhammer, T., Chiba, P., and Moeslinger, T. (2009) Aqueous extracts of Cimicifuga racemosa and phenolcarboxylic constituents inhibit production of proinflammatory cytokines in LPS-stimulated human whole blood, Can. J. Physiol. Pharmacol., 87, 963–972.CrossRefPubMedGoogle Scholar